Marc R. Theoret

United States Food and Drug Administration

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 40 papers. Top paper: “FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma”.

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3803

N/A

2.6DataRank · unranked

94 citations

Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan +3 more

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2036

N/A

1.6DataRank · unranked

60 citations

Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani +12 more

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1272

N/A

1.4DataRank · unranked

35 citations

Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, P Li +8 more

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0327

N/A

0.957DataRank · unranked

589 citations

Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher +7 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0.773DataRank · unranked

172 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2234

N/A

0.739DataRank · unranked

24 citations

Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C.Y. Chow, Ruo‐Jing Li +7 more

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Journal of Clinical Oncology(2023)10.1200/jco.23.00225

N/A

0.731DataRank · unranked

130 citations

Yvette Kasamon, Marc R. Theoret, Richard Pazdur, Paul Kluetz, Nicole Gormley +1 more

Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2628

N/A

0.605DataRank · unranked

4 citations

Jörge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler +11 more

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0850

N/A

0.524DataRank · unranked

32 citations

James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur +2 more

FDA Approval Summary: Teclistamab–A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1872

N/A

0.416DataRank · unranked

15 citations

Bindu Kanapuru, Jay Zhao, Lauren Price, Nan Zheng, Robyn Konicki +5 more

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1086

N/A

0.385DataRank · unranked

12 citations

Edwin C.Y. Chow, Alexei Ionan, Haiyan Chen, Shwu‐Luan Lee, Vicky Hsu +10 more

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2196

N/A

0.360DataRank · unranked

10 citations

Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo +12 more

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1035

N/A

0.292DataRank · unranked

6 citations

Upendra Mahat, Nicholas C. Richardson, Million A. Tegenge, Qianmiao Gao, Marc R. Theoret +2 more

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0896

N/A

0.241DataRank · unranked

4 citations

Kamar Godder, Jingyan Wang, Justin S. Collazo, Robyn Konicki, Moran Choe +15 more

Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0826

N/A

0.241DataRank · unranked

4 citations

Elisabetta Abruzzese, Elyce Cardonick, Sonia Hernández–Dı́az, Jamie Gutierrez, Mary S. Sardegna +10 more

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia

Journal of Clinical Oncology(2025)10.1200/jco-25-01369

N/A

0.104DataRank · unranked

1 citations

Dianne Pulte, Lori A. Ehrlich, Alexei Ionan, Spencer R. Haupert, Jonathon Vallejo +15 more

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3579

N/A

0DataRank · unranked

11 citations

Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru +7 more

Considerations for Drug Development in Myelodysplastic Syndromes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3348

N/A

0DataRank · unranked

12 citations

Nina Kim, Amy E. DeZern, Kelly J. Norsworthy, Jacqueline S. Garcia, R. Angelo de Claro +6 more

FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3240

N/A

0DataRank · unranked

0 citations

Julia Eckstein, Kirsten B. Goldberg, Mark C. Ascione, Thamar Bailey, Kimberly Taylor +8 more

FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0378

N/A

0DataRank · unranked

42 citations

Megha Kaushal, Bindu George, Bindu Kanapuru, Marc R. Theoret, Kavita Natrajan

Improving Collection and Analysis of Overall Survival Data

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0919

N/A

0DataRank · unranked

17 citations

Nicole Gormley, Ruixiao Lu, Anup Amatya, George D. Demetri, Keith T. Flaherty +12 more

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1729

N/A

0DataRank · unranked

7 citations

Yvette L. Kasamon, Wenjuan Gu, Lisa R. Rodriguez, Susan Jin, Vishal Bhatnagar +5 more

Project Confirm: Accelerated Drug Approvals for CML—Response

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3234

N/A

0DataRank · unranked

0 citations

Jörge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler +12 more

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0880

N/A

0DataRank · unranked

14 citations

Chaohong Fan, Peter Bross, Asha Das, Elin S. Cho, Karin M. Knudson +6 more

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4181

N/A

0DataRank · unranked

8 citations

Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R. Theoret, Robert Sokolic +2 more

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology

Journal of Clinical Oncology(2025)10.1200/jco-25-00488

N/A

0DataRank · unranked

6 citations

Mirat Shah, Mark J. Ratain, Elizabeth Garrett‐Mayer, Atiqur Rahman, Marc R. Theoret +2 more

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1005

N/A

0DataRank · unranked

5 citations

Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Nan Zheng +10 more

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1034

N/A

0DataRank · unranked

4 citations

Shu Wang, Ritu Chadda, Donna Przepiorka, Jonathon Vallejo, Xiling Jiang +3 more

Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4325

N/A

0DataRank · unranked

1 citations

Nicole Drezner, Stacy S. Shord, Mirat Shah, Marc R. Theoret, Martha Donoghue +1 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3901

N/A

0DataRank · unranked

101 citations

Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li +16 more

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4429

N/A

0DataRank · unranked

4 citations

Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani +13 more

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4557

N/A

0DataRank · unranked

164 citations

Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow +14 more

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4176

N/A

0DataRank · unranked

56 citations

Robert Q. Le, Alexei Ionan, Ruo‐Jing Li, Yinghong Wang, Ramadevi Gudi +16 more

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0618

N/A

0DataRank · unranked

56 citations

Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li +8 more

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4525

N/A

0DataRank · unranked

25 citations

Xin Wang, Meng Li, Hongshan Li, Shwu‐Luan Lee, Nina Ni +9 more

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2400

N/A

0DataRank · unranked

12 citations

Leslie Doros, Margaret Thompson, Sirisha L. Mushti, Rosane Charlab, Elizabeth I. Spehalski +8 more

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0557

N/A

0DataRank · unranked

180 citations

Leigh Marcus, Lola A. Fashoyin‐Aje, Sirisha L. Mushti, Joyce Cheng, Yuan Li Shen +8 more

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0568

N/A

0DataRank · unranked

24 citations

Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc R. Theoret, Tejashri Purohit-Sheth +1 more